polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Ginger, 500 mg, 4 doses daily, for 12 weeks. Intervention 2: Control group: Placebo, 500mg, 4 doses daily, for 12 weeks.
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age above 18 years BMI above 18.5 Diagnosis and confirmation of polycystic ovary syndrome by an endocrinologist and metabolism specialist based on the Rotterdam criteria Willingness to cooperate
Exclusion criteria
Exclusion criteria: Unwillingness to participate in the study Pregnancy Lactation Menopause Having other causes of hyperandrogenism such as congenital adrenal hyperplasia, Cushing's syndrome, ovarian or adrenal tumor Having any type of disease that affects hormonal parameters, such as hypoglycemia, diabetes, hyperprolactinemia, hyperparathyroidism, thyroid disorders, hypertension, anemia, allergies, asthma, cardiovascular, kidney, liver, lung, and cancer. Taking ginger supplements in the last three months Anticoagulant, diabetes and blood pressure medications (due to interference with ginger) during the study Following special diets
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;High density lipoprotein cholesterol. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Interleukin 6. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Total antioxidant capacity. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Malondialdehyde. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Anti mullerian hormone. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Leptin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Testosterone. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Sex hormone binding globulin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Insulin resistance. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: HOMA-IR.;Insulin sensitivity. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: QUICKI.;Fasting blood sugar. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Glycosylated hemoglobin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Serum insulin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: ELISA Kit.;Triglycerides. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Heidari
Ahvaz University of Medical Sciences
Outcome results
None listed